John Sullivan Headshot image

BioHealth Innovation, Inc. (BHI) announced today that John P. Sullivan has joined BHI as a new Entrepreneur-in-Residence (EIR) for the National Institutes of Health (NIH), working with Ethel Rubin, PhD, ventures team head, to provide product, corporate and private investment strategy for NIH portfolio companies.

“We are pleased to have Mr. Sullivan join the team of EIRs serving NIH,” said Richard Bendis, BHI President and CEO. “His expertise in building, operating and acquiring health technology businesses will certainly be an asset as he works to provide the institution with industry insights and commercialization perspectives.”

Established with NIH in 2012, the EIR program is designed to connect NIH-funded start-ups with experienced industry experts who can help them maneuver through multi-disciplinary technical challenges and the business and regulatory environment to deploy new healthcare and biomedical technologies. 

bhi updated logo 2017

A sign of the BioHealth Capital Region’s industry growth is the increase in hiring taking place throughout the region.   More than 1800 job opportunities are listed on BioHealth Innovation’s website (www.BioHealthInnovation.org/Jobs).  Many with relatively young companies expanding their regulatory, manufacturing and R&D teams.  To post positions, Email:  This email address is being protected from spambots. You need JavaScript enabled to view it..

bhi sbir logo

HOLD THE DATE - January 29, 2019  8 am. – 12:30 p.m.

Meet 1:1 with SBIR program managers. Learn more about their funding programs (SBIR and more!) 

8-8:30 Networking and Registration

8:30 – 10:00 a.m. – Program Overviews*

10:00 – 12:30 p.m. – 1:1 Meetings with Program Managers**

Agencies represented include:   
NSF, NIH NIA, NIH NCATS, NIH NCI, NIH NHLBI, NIH NIDA, US Army (invited)


*The program overview will be available by videoconference.

**You do not have to participate in 1:1 meetings.  However, to do so, you must attend the overview session in person.
PRE-REGISTRATION IS REQUIRED:  RSVP by noon 1/27:  This email address is being protected from spambots. You need JavaScript enabled to view it.

christiana-aronson-headshot-image.png

Join us for the January 23, 2019 for PATHFINDER INNOVATION PROGRAM

Learn more about:

  • Overview and Reporting Requirements for Type of Entity
  • Impact of Accounting Methods 
  • Start-up Company Issues
  • International Investment
  • Tax Law Changes
  • State Tax Concerns
  • Tax Planning

Schedule

12:00 p.m - Networking Lunch

12:30 - 1:30 p.m. - Discussion with Q&A*  - Tom Christiana, Partner – Aronson, LLC

1:30 – 4:00 p.m. - One-on-one Meetings**

RSVP by noon, January 22, at This email address is being protected from spambots. You need JavaScript enabled to view it.

No charge to attend but pre-registration is required.*Attend in person (1 Church St, Rockville) or by videoconference**Attendance at discussion is required to participate in 1:1

Download Flyer »

christy-wyskiel-jhu-image

Please join me in celebrating two exciting leadership changes at JHTV. Steve Kousouris, who has been serving as Interim Executive Director of Technology Transfer at JHTV since June, has assumed this role permanently effective Jan.1. Additionally, Mark Bailey, previously Associate Director of Finance, will assume responsibility for the portfolio that Steve has overseen since 2013 in the capacity of Director, Finance & Administration.

autolus-logo

Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has signed a long-term, full-building lease with Alexandria Real Estate Equities, Inc. (NYSE: ARE) for the construction and development of an 85,000 square foot build-to-suit facility to be located in the Shady Grove Life Sciences Center in Rockville, Maryland. The new facility will house offices for Autolus' U.S.-based research and development, commercial and corporate functions and serve as its first full commercial-scale manufacturing center, with a planned capacity to produce 5,000 T cell therapies annually. In addition, Autolus has established a temporary U.S. headquarters in Rockville until the new facility is ready for occupancy, which is currently expected to occur in 2021.

biopharma-laboratory-lab-pixa

2018 was a record year for biopharma initial public offerings (IPOs), with an all-time high of $6.3 billion raised by 58 U.S. companies as of December 17, according to Renaissance Capital, compared with 36 companies garnering some $4 billion in 2017.

pharma-pills-pixa

For months, it had been clear that 2018 would be a banner year for pharmaceutical innovation. The question was, by how much would it shatter the previous (1996) record of 50 approvals (excluding diagnostics and imaging agents)? We now know. It exceeded it by over 20 percent. Last year, U.S. regulators approved a total of 61 drugs – 59 by FDA’s Center for Drug Evaluation and Research (CDER), plus two recombinant therapies (Andexxa and Jivi) by its Center for Biologics Evaluation and Research (CBER).

pharma-drugs-pixa

Pharmaceutical companies are starting to see the retail supply chain as more than just a way to get drugs from point A to point B. It can be an opportunity to ensure better products and services and create a competitive advantage with consumers – but only if data is connected and well managed.

childrens-national-health-system-logo

Is the pain stabbing or burning? On a scale from 1 to 10, is it a 6 or an 8?

Over and over, 17-year-old Sarah Taylor struggled to make doctors understand her sometimes debilitating levels of pain, first from joint-damaging childhood arthritis and then from fibromyalgia.

umd-jhu-logos

MOVE over Caltech, Georgia Tech, and MIT – the University of Oxford has been named the best university in the world for computer science degrees for 2019. The ranking compares the top computer science programs in the world. ETH Zurich ranked number 2 on the list, followed by Stanford University (No. 3), the University of Cambridge (No. 4), and Massachusetts Institute of Technology (No. 5).

umd-fischell-collage-image

The University of Maryland Robert E. Fischell Institute for Biomedical Devices celebrated its official launch on Thursday, January 3, 2019. The event kicked off included presentations by researchers at the Institute and supported by the the Institute taking place at the A. James Clark School of Engineering, the University of Maryland School of Medicine, Children’s National Health Center, University of Maryland Insitute for Bioscience and Biotechnology Research.

bhi launch tedco mont county logo

Wednesday, January 23, 2019, 12:30 - 4:00pm

Are you a young company or thinking of starting up a new firm.  What do you need to know related to taxes?  --tax credits? Filing? Tax liability? Other accounting issues? Learn the answers to these questions and more.

This email address is being protected from spambots. You need JavaScript enabled to view it. to participate in person / by video conference**       

  • 12:00 p.m. - Networking Lunch   
  • 12:30-1:30 p.m. - Panel and Q&A with experts
  • 1:30 p.m. - 1:1 meetings*

*Attendance at Panel is required to participate in 1:1 meeting with expert.

**In person at BHI HQ, 1 Church Street, Rockville, MD or by videoconference.

alexandria joel marcus logo

Congrats to Alexandria a BHI partner and Board Member for their commitment to early-stage BioHealth investing.

Alexandria Venture Investments, the strategic venture capital arm of Alexandria Real Estate Equities, Inc. based in Pasadena, was recognized by Silicon Valley Bank as the most active biopharma investor by new deal volume in 2017-2018.

Fraser_Claire-umd-image.jpg

University of Maryland School of Medicine (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today that Claire M. Fraser, PhD, a pioneer in the field of microbialgenomics, who is the Dean’s Endowed Professor, Department of Medicine, and Director of the Institutefor Genome Sciences (IGS), has been chosen as president-elect of the American Association for the Advancement of Science (AAAS). AAAS is the world’s largest multidisciplinary scientific society and a leading publisher of cutting edge research through its Science family of journals.

milken-state-tech-index-2018-logo

The STSI's 107 individual indicators are sorted into five composites: research and development (R&D) inputs, risk capital and entrepreneurial infrastructure, human capital investment, technology and science workforce, and technology concentration and dynamism.

dna-genetics-pixa

The first Food and Drug Administration approvals for cell and gene therapies are already more than a year out, but 2019 is likely to be a significant year for the field, particularly in areas like international interest, industry consolidation and pricing. That was the theme of a panel discussion Monday morning at Biotech Showcase in San Francisco, which coincides with the 2019 J.P. Morgan Healthcare Conference.

america-gene-technologies-logo

In wrapping up the year, AGT was proud to be featured as a State of Maryland “Success Story” for its growth in Maryland and achievements in the gene and cell therapy industry.

jp-morgan-healthcare-conference-logo

Now in its 37th year, the conference has ballooned from a small event with 150 attendees that was essentially the " birth of biotech," to an event attended by everyone from the biggest pharma company to the smallest biotech. JPMorgan said more than 485 companies are scheduled to present this year.

Bahija-Jallal-MedImmune-image

Congratulations to Bahija on making MedImmune the leading BioHealth company in Maryland and accelerating its growth. Also many thanks for the MedImmune longtime support of BHI and helping the BioHealth Capital Region become the 4th largest Life Science region in the country.

Six years after AstraZeneca’s then new CEO Pascal Soriot named Bahija Jallal president of the big MedImmune subsidiary in Gaithersburg, MD, putting her at the center of the company’s R&D turnaround plans, the longtime pharma exec is joining the great migration of industry professionals to biotech.

emergent-abdun-nabi-kramer-2-image.png

Many thanks to Dan for his leadership of Emergent, his service as a loyal BHI Board Member and for helping accelerate the growth of the BIO Health Capital Region

Emergent BioSolutions Inc. (EBS) today announced that its CEO Daniel J. Abdun-Nabi will be retiring and that its board of directors has unanimously appointed Robert G. Kramer, Sr., the company’s current president and COO, to succeed him as president and CEO, effective April 1, 2019. Mr. Abdun-Nabi has also indicated that he plans to step down as a member of the Emergent board of directors, and Emergent expects the board of directors to appoint Mr. Kramer to fill the board vacancy created by Mr. Abdun-Nabi’s retirement.